EXAMINE Trial logo

Exploring the Cardiovascular Safety of Therapies for Type 2 Diabetes

News for the EXAMINE Trial

  • New 2018 Publications from EXAMINE
    Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Garlo KG, White WB, Bakris GL, Zannad F, Wilson CA, Kupfer S, Vaduganathan M, Morrow DA, Cannon CP, Charytan DM. Clin J Am Soc Nephrol. 2018 Jan 16. pii: CJN.05280517. doi: 10.2215/CJN.05280517. [Epub ahead of print] PMID: 29339356
    Posted on January 29, 2018
  • New 2017 Publications from EXAMINE
    High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WB. Diabetes Obes Metab. 2017 Oct 24. doi: 10.1111/dom.13136. [Epub ahead of […]
    Posted on January 29, 2018
  • New Presentations from the EASD, Lisbon, Portugal, September 11-14, 2017
    Cardiovascular Outcome Trials in Type 2 Diabetes: Lessons Learned and Future Outlook Total Cardiovascular Events Analysis of the EXAMINE Trial of Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome High Sensitivity C-Reactive Protein, Low-Density Cholesterol, and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Acute Coronary Syndrome From the EXAMINE Trial Visit-to-Visit […]
    Posted on September 7, 2017
  • New 2016 Publications from EXAMINE
    Cardiovascular Effects of Incretin-Based Therapies. White WB, Baker WL. Annu Rev Med. 2016;67:245-60. doi: 10.1146/annurev-med-050214-013431. Review. PMID: 26768240 Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Heller SK, Mehta CR, Nissen […]
    Posted on September 7, 2017
  • Diabetes Drug Shown Not to Increase Heart Failure Risk
    People with the most common form of diabetes can take the new drug Alogliptin without concern for an increased risk of heart failure or cardiovascular disease, according to research by a UConn cardiologist just published in the British medical journal, The Lancet.
    Posted on March 13, 2015
EXAMINE: EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE

EXAMINE Trial, Enrollment by Region

Trial Overview   Primary Results

Contact Us

William B. White, M.D., FASH, FAHA, FACP
Professor of Medicine
Chair, EXAMINE Steering Committee

Pat and Jim Calhoun Cardiology Center
UConn School of Medicine
263 Farmington Avenue
Farmington, CT 06030-3940

Email: webster@uchc.edu